PHAXIAM Therapeutics S.A.
PHXM
Rang în acțiuni
#39387
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Preț acțiune
$0.11725176
Ultima sincronizare: 2025-07-14
Capitalizare de piață
$481.50K
Schimbare (1 zi)
-0.20%
Schimbare (1 an)
-1.64%
Țară
FR
Tranzacționează PHAXIAM Therapeutics S.A. (PHXM)
Categorie
Healthcare
EPS pentru PHAXIAM Therapeutics S.A. (PHXM)
EPS la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor PHAXIAM Therapeutics S.A., EPS-ul actual al companiei (TTM) este 0. La sfârșitul anului 2026, compania avea un EPS de 0 egal cu EPS-ului din 2026, care a fost de 0.
Istoricul EPS pentru PHAXIAM Therapeutics S.A. din 2026 până în 2026
EPS la sfârșitul fiecărui an
| An | EPS | Schimbă |
|---|---|---|
| Nu sunt suficiente date pentru perioada selectată. | ||
EPS pentru companii similare sau concurente
| Companie | EPS | Diferență EPS | Țara |
|---|---|---|---|
| $17.32 | - |
US
|
|
| $-7.98 | - |
US
|
|
| $-5.29 | - |
AU
|
|
| - | - |
CH
|
|
| $27.74 | - |
NL
|
